Compare GSK plc (GSK) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs ProShares Ultra QQQ ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while ProShares Ultra QQQ ETF trades at $98.43 (market cap $15.38B). The key difference: GSK plc is far larger — about 6× ProShares Ultra QQQ ETF's market cap, and GSK plc pays a 3.9% dividend while ProShares Ultra QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and ProShares Ultra QQQ ETF for 36 Days on average.
| GSK | QLD | |
|---|---|---|
Market Cap | $91.88B | $15.38B |
Volume | 7,730,529 | 4,844,085 |
Sector | Health | Leveraged / Inverse |
52-Week High | $61.18 | $100.77 |
52-Week Low | $43.24 | $57.16 |
Typical Hold Time | 93 Days | 36 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
QLD (ProShares Ultra QQQ ETF) trades at $97.56, down 2.66% amid broader market volatility. Technical indicators show a bullish moving average signal but neutral oscillators, with key support at $96 and resistance at $100. The ETF provides 2x leveraged exposure to the Nasdaq-100, attracting institutional interest as evidenced by recent buying activity from 180 Wealth Advisors. Recent news highlights QLD's resilience compared to higher-leverage alternatives during market downturns.
The outlook for QLD remains tied to Nasdaq-100 performance and Federal Reserve policy. While technical momentum appears positive, investors face amplified volatility risks inherent to leveraged products. The ETF's 2x leverage structure offers middle-ground exposure that may appeal to tactical investors seeking Nasdaq-100 upside with less extreme risk than 3x products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
